Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Discovery of potent inhibitors of the lysophospholipase autotaxin.

Shah P, Cheasty A, Foxton C, Raynham T, Farooq M, Gutierrez IF, Lejeune A, Pritchard M, Turnbull A, Pang L, Owen P, Boyd S, Stowell A, Jordan A, Hamilton NM, Hitchin JR, Stockley M, MacDonald E, Quesada MJ, Trivier E, Skeete J, Ovaa H, Moolenaar WH, Ryder H.

Bioorg Med Chem Lett. 2016 Oct 14. pii: S0960-894X(16)31064-2. doi: 10.1016/j.bmcl.2016.10.036. [Epub ahead of print]

PMID:
27780639
2.

High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors.

Myers SM, Bawn RH, Bisset LC, Blackburn TJ, Cottyn B, Molyneux L, Wong AC, Cano C, Clegg W, Harrington RW, Leung H, Rigoreau L, Vidot S, Golding BT, Griffin RJ, Hammonds T, Newell DR, Hardcastle IR.

ACS Comb Sci. 2016 Aug 8;18(8):444-55. doi: 10.1021/acscombsci.5b00155.

PMID:
27400250
3.

Histopathological characteristics of renal changes in human renin-angiotensinogen double transgenic rats.

Tochitani T, Mori M, Matsuda K, Kouchi M, Fujii Y, Matsumoto I.

J Toxicol Pathol. 2016 Apr;29(2):125-9. doi: 10.1293/tox.2015-0055.

4.

EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.

Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Möller P, Brüderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM.

J Pathol. 2016 Jul;239(3):320-34. doi: 10.1002/path.4729.

5.

Parental preferences regarding administration of an animal-derived versus a synthetic medication to newborn infants.

Sherman TI, Moya F, Simmons PD, Kurtz D, Shaffer TH.

J Neonatal Perinatal Med. 2016;9(1):7-14. doi: 10.3233/NPM-16915062.

PMID:
27002267
6.

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ.

Cell Cycle. 2016;15(4):506-18. doi: 10.1080/15384101.2015.1120915.

7.

Therapeutic targeting of casein kinase 1δ in breast cancer.

Rosenberg LH, Lafitte M, Quereda V, Grant W, Chen W, Bibian M, Noguchi Y, Fallahi M, Yang C, Chang JC, Roush WR, Cleveland JL, Duckett DR.

Sci Transl Med. 2015 Dec 16;7(318):318ra202. doi: 10.1126/scitranslmed.aac8773.

8.

Characterization of a nose-only inhaled phosgene acute lung injury mouse model.

Plahovinsak JL, Perry MR, Knostman KA, Segal R, Babin MC.

Inhal Toxicol. 2015;27(14):832-40. doi: 10.3109/08958378.2015.1117549.

9.

Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S, Toguchida J.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15438-43. doi: 10.1073/pnas.1510540112.

10.

LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.

Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, McGarry L, Rath O, Shanks E, Garnett MJ, McDermott U, Brookfield J, Charles M, Hammonds T, Olson MF.

Oncotarget. 2015 Nov 17;6(36):38469-86. doi: 10.18632/oncotarget.6288.

11.

Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion.

Saunders VC, Lafitte M, Adrados I, Quereda V, Feurstein D, Ling Y, Fallahi M, Rosenberg LH, Duckett DR.

Mol Pharmacol. 2015 Dec;88(6):962-9. doi: 10.1124/mol.115.097774.

12.

Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.

Hammonds T.

Future Med Chem. 2015;7(14):1891-9. doi: 10.4155/fmc.15.111.

PMID:
26393391
13.

One-Step Synthesis of 2-Chloropyrimidin-4-ol Derivatives: An Unusual Reactivity of Thiophosgene.

Callingham M, Blum F, Pavé G.

Org Lett. 2015 Oct 2;17(19):4930-2. doi: 10.1021/acs.orglett.5b02375.

PMID:
26360817
14.

Discovery, Development, and SAR of Aminothiazoles as LIMK Inhibitors with Cellular Anti-Invasive Properties.

Charles MD, Brookfield JL, Ekwuru TC, Stockley M, Dunn J, Riddick M, Hammonds T, Trivier E, Greenland G, Wong AC, Cheasty A, Boyd S, Crighton D, Olson MF.

J Med Chem. 2015 Oct 22;58(20):8309-13. doi: 10.1021/acs.jmedchem.5b01242.

PMID:
26356364
15.

DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats.

Kato T, Matsumoto Y, Yamamoto M, Matsumoto K, Baba S, Nakamichi K, Matsuda H, Nishimuta H, Yabuuchi K.

Pharmacol Res Perspect. 2015 Jun;3(3):e00142. doi: 10.1002/prp2.142.

16.

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition.

Sadaie M, Dillon C, Narita M, Young AR, Cairney CJ, Godwin LS, Torrance CJ, Bennett DC, Keith WN, Narita M.

Mol Biol Cell. 2015 Sep 1;26(17):2971-85. doi: 10.1091/mbc.E15-01-0003. Erratum in: Mol Biol Cell. 2015 Oct 1;26(19):3556. Narita, Masashi [Corrected to Narita, Masako].

17.
18.

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3.

Boyd S, Brookfield JL, Critchlow SE, Cumming IA, Curtis NJ, Debreczeni J, Degorce SL, Donald C, Evans NJ, Groombridge S, Hopcroft P, Jones NP, Kettle JG, Lamont S, Lewis HJ, MacFaull P, McLoughlin SB, Rigoreau LJ, Smith JM, St-Gallay S, Stock JK, Turnbull AP, Wheatley ER, Winter J, Wingfield J.

J Med Chem. 2015 Apr 23;58(8):3611-25. doi: 10.1021/acs.jmedchem.5b00352.

PMID:
25849762
19.

DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent antidepressant and antimanic activity.

Kato T, Takata M, Kitaichi M, Kassai M, Inoue M, Ishikawa C, Hirose W, Yoshida K, Shimizu I.

Eur J Pharmacol. 2015 Jun 15;757:11-20. doi: 10.1016/j.ejphar.2015.03.024.

PMID:
25823809
20.

The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets.

Baba S, Murai T, Nakako T, Enomoto T, Ono M, Shimizu I, Ikeda K.

Behav Brain Res. 2015;287:120-6. doi: 10.1016/j.bbr.2015.03.025.

PMID:
25804359
Items per page

Supplemental Content

Loading ...
Support Center